Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
复制标题
DOI：
10.1200/jco.2003.02.022
复制
发表时间：
2003-03-15
影响因子：
45.3
通讯作者：
Katsaros, D
中科院分区：
文献类型：
--
作者：
Diamandis, EP;Scorilas, A;Katsaros, D
目的：发现适用于早期疾病诊断和预后的新的卵巢癌生物标志物可能最终改善患者管理和预后。患者和方法：我们用免疫测定法测定了97名表面健康妇女、141名腹部良性疾病妇女和146名组织学证实的原发性卵巢癌妇女的血清中人钾化因子6 （hK6）的浓度。然后，我们计算了该测试的诊断敏感性和特异性，并检查了血清hK6浓度与各种临床病理变量和患者生存率的关系。结果：正常和良性疾病患者血清hK6浓度无显著差异（平均值分别为2.9和3.1马克杯/L）。而卵巢癌患者术前血清hK6明显升高（平均6.8 mg /L, P < 0.001）。68%的患者术后血清hK6下降（平均为3.9马克杯/升）。在整个患者群体中，血清hK6在90%和95%特异性的诊断敏感性分别为52%和47%。对于早期疾病（I期或II期），敏感性约为21%至26%。当与CA- 125联合使用时，特异性为90%，敏感性增加到72%（所有患者），在I期或II期疾病中增加到42%。血清hK6浓度与CA-125中度相关，在晚期、高级别疾病患者和浆液组织型患者中较高。术前血清hK6浓度在单因素和多因素分析中都是无病和总生存的有力预测因子。结论：血清hK6浓度可能是卵巢癌的一种新的生物标志物，对疾病的诊断和预后可能有价值。[J]中华临床杂志，21(10):335 - 343。(C) 2003年由美国临床肿瘤学会出版。
Purpose : The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes.Patients and Methods: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. We then calculated the diagnostic sensitivity and specificity of this test and examined the association of serum hK6 concentration with various clinicopathologic variables and patient survival.Results: Serum hK6 concentration between normal and benign disease patients was not different (mean, 2.9 and 3.1 mug/L, respectively). However, hK6 in presurgical serum of ovarian cancer patients was highly elevated (mean, 6.8 mug/L; P < .001). Serum hK6 decreased after surgery (to a mean of 3.9 mug/L) in 68% of patients. The diagnostic sensitivity of serum hK6 at 90% and 95% specificity is 52% and 47%, respectively, in the whole patient population. For early stage disease (stage I or II), sensitivity is approximately 21% to 26%. When combined with CA- 125, at 90% specificity, sensitivity increases to 72% (for all patients) and to 42% in stage I or II disease. Serum hK6 concentration correlates moderately with CA-125 and is higher in patients with late-stage, higher-grade disease and in patients with serous histotype. Preoperative serum hK6 concentration is a powerful predictor of disease-free and overall survival in both univariate and multivariate analyses.Conclusions: Serum hK6 concentration seems to be a new biomarker for ovarian carcinoma and may have value for disease diagnosis and prognosis. J Clin Oncol 21:1035-1043. (C) 2003 by American Society of Clinical Oncology.